Detoxicare Molecular Diagnostics Laboratory forged a partnership deal with a global patient-focused biopharmaceutical company AstraZeneca for next-generation sequencing for breast cancer.“Detoxicare’s commitment to making advanced diagnostics affordable and within reach has been a driving force in reshaping the landscape of healthcare accessibility,” said Gjay Ordinal, president of Detoxicare Molecular Diagnostics Laboratory.
“By combining the pharmaceutical expertise of AstraZeneca with Detoxicare’s proficiency in molecular diagnostics, we are poised to usher in a new era of personalized medicine,” Ordinal said. Integrating advanced technologies into clinical practice will be instrumental in personalizing treatment approaches, optimizing therapeutic efficacy, and ultimately improving patient survival and quality of life, especially in the Philippines where breast and ovarian cancer are two of the most prevalent types afflicting Filipinos.In the field of oncology, biomarker testing plays a pivotal role in identifying specific molecular characteristics of tumors and guiding treatment decisions.
When combined with next-generation sequencing , medical experts gain comprehensive insights into the genetic mutations and alterations driving cancer progression, allowing for tailored treatments with unprecedented precision. Lotis Ramin, AstraZeneca country president said: “We are redefining oncology in AstraZeneca, where we aspire for a future where cancer cure is possible through our life-changing medicines, alongside partnerships and ecosystem solutions that allow early detection, diagnosis, and equitable cancer care for patients.”